EUR 0.61
(1.17%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 1.00 USD | 100.0% |
2022 | -11.2 Million USD | 65.99% |
2021 | -32.93 Million USD | -1141.62% |
2020 | 3.16 Million EUR | 38.51% |
2019 | 2.28 Million EUR | 27.44% |
2018 | 1.79 Million EUR | -27.3% |
2017 | 2.46 Million EUR | 0.0% |
2016 | - EUR | -100.0% |
2015 | 2.02 Million EUR | 1240.62% |
2014 | 150.87 Thousand EUR | 1563.49% |
2013 | 9069.57 EUR | -76.89% |
2012 | 39.24 Thousand EUR | -12.11% |
2011 | 44.64 Thousand EUR | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | 1.00 EUR | -100.0% |
2024 Q1 | 1.72 Million USD | -17.88% |
2023 Q2 | -15.28 Million USD | -749.66% |
2023 Q1 | 2.35 Million USD | -12.24% |
2023 FY | 1.00 USD | 100.0% |
2023 Q4 | 2.1 Million USD | 112.41% |
2023 Q3 | -16.94 Million USD | -10.86% |
2022 FY | -11.2 Million USD | 65.99% |
2022 Q4 | 2.68 Million USD | 0.0% |
2022 Q1 | 3.38 Million USD | 110.28% |
2022 Q2 | 3.77 Million USD | 11.43% |
2022 Q3 | - USD | -100.0% |
2021 Q2 | - USD | 0.0% |
2021 Q1 | - USD | -100.0% |
2021 Q3 | - USD | 0.0% |
2021 Q4 | -32.93 Million USD | 0.0% |
2021 FY | -32.93 Million USD | -1141.62% |
2020 Q4 | 3.16 Million EUR | 0.0% |
2020 Q2 | 3.75 Million EUR | 0.0% |
2020 FY | 3.16 Million EUR | 38.51% |
2019 Q4 | 2.28 Million EUR | -7.14% |
2019 Q2 | 2.36 Million EUR | 0.0% |
2019 Q3 | 2.45 Million EUR | 3.85% |
2019 FY | 2.28 Million EUR | 27.44% |
2018 FY | 1.79 Million EUR | -27.3% |
2018 Q4 | 1.79 Million EUR | 0.0% |
2018 Q2 | - EUR | 0.0% |
2017 Q2 | - EUR | 0.0% |
2017 Q4 | 2.46 Million EUR | 0.0% |
2017 FY | 2.46 Million EUR | 0.0% |
2016 Q4 | - EUR | 0.0% |
2016 FY | - EUR | -100.0% |
2016 Q2 | 1.00 EUR | 0.0% |
2015 Q4 | 2.02 Million EUR | 0.0% |
2015 Q2 | 154.6 Thousand EUR | 0.0% |
2015 FY | 2.02 Million EUR | 1240.62% |
2014 Q2 | 9255.37 EUR | 0.0% |
2014 Q4 | 150.87 Thousand EUR | 0.0% |
2014 FY | 150.87 Thousand EUR | 1563.49% |
2013 FY | 9069.57 EUR | -76.89% |
2013 Q4 | 9069.57 EUR | 0.0% |
2013 Q2 | 15.89 Thousand EUR | 0.0% |
2012 Q4 | 39.24 Thousand EUR | 0.0% |
2012 FY | 39.24 Thousand EUR | -12.11% |
2012 Q2 | 31.73 Thousand EUR | 0.0% |
2011 Q4 | 44.64 Thousand EUR | 0.0% |
2011 FY | 44.64 Thousand EUR | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
ABIONYX Pharma SA | 221 Thousand EUR | 100.0% |
ABIVAX Société Anonyme | 1.00 EUR | 0.0% |
Adocia SA | 272 Thousand EUR | 100.0% |
Aelis Farma SA | 53 Thousand EUR | 99.998% |
Biophytis S.A. | - EUR | -Infinity% |
Advicenne S.A. | 1.74 Million EUR | 100.0% |
genOway Société anonyme | 982.75 Thousand EUR | 100.0% |
IntegraGen SA | 311.44 Thousand EUR | 100.0% |
Medesis Pharma S.A. | 164.62 Thousand EUR | 99.999% |
Neovacs S.A. | - EUR | -Infinity% |
NFL Biosciences SA | -1.1 Million EUR | 100.0% |
Plant Advanced Technologies SA | 1.22 Million EUR | 100.0% |
Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 100.001% |
Sensorion SA | - EUR | -Infinity% |
Theranexus Société Anonyme | - EUR | -Infinity% |
TME Pharma N.V. | 91 Thousand EUR | 99.999% |
Valbiotis SA | 1 Million EUR | 100.0% |
TheraVet SA | 123.34 Thousand EUR | 99.999% |
Valerio Therapeutics Société anonyme | 1.00 EUR | 0.0% |
argenx SE | 281.12 Million EUR | 100.0% |
BioSenic S.A. | - EUR | -Infinity% |
Celyad Oncology SA | 1.26 Million EUR | 100.0% |
Galapagos NV | 73.97 Million EUR | 100.0% |
Genfit S.A. | 4000.00 EUR | 99.975% |
GeNeuro SA | - EUR | -Infinity% |
Hyloris Pharmaceuticals SA | 1.00 EUR | 0.0% |
Innate Pharma S.A. | 1.00 EUR | 0.0% |
Inventiva S.A. | 417 Thousand EUR | 100.0% |
MaaT Pharma SA | 190 Thousand EUR | 99.999% |
MedinCell S.A. | -6.71 Million EUR | 100.0% |
Nanobiotix S.A. | 200 Thousand EUR | 100.0% |
Onward Medical N.V. | 936 Thousand EUR | 100.0% |
Oryzon Genomics S.A. | 6029.00 EUR | 99.983% |
OSE Immunotherapeutics SA | - EUR | -Infinity% |
Oxurion NV | 128 Thousand EUR | 99.999% |
Pharming Group N.V. | 51.38 Million EUR | 100.0% |
Poxel S.A. | 2.95 Million EUR | 100.0% |
GenSight Biologics S.A. | 1.00 EUR | 0.0% |
Transgene SA | - EUR | -Infinity% |
Financière de Tubize SA | - EUR | -Infinity% |
UCB SA | 1.03 Billion EUR | 100.0% |
Valneva SE | 44.46 Million EUR | 100.0% |
Vivoryon Therapeutics N.V. | 1.00 EUR | 0.0% |